Loading…
DiaMedica Therapeutics Inc. is projected to rise to $9.03 by 2027, a +18% move from its current price of $7.67. DMAC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $7.45 | $7.67 | $7.90 | +0.02% |
| Jul 14 | $7.36 | $7.67 | $8.00 | +0.05% |
| Jul 15 | $7.29 | $7.68 | $8.08 | +0.07% |
| Jul 16 | $7.23 | $7.68 | $8.15 | +0.09% |
| Jul 17 | $7.19 | $7.68 | $8.21 | +0.11% |
| Jul 18 | $7.14 | $7.68 | $8.26 | +0.14% |
| Jul 19 | $7.10 | $7.68 | $8.31 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.10 | $7.68 | $8.31 | +0.16% |
| Week 2 | $6.89 | $7.69 | $8.60 | +0.32% |
| Week 3 | $6.73 | $7.71 | $8.83 | +0.48% |
| Week 4 | $6.60 | $7.72 | $9.03 | +0.64% |
| Week 5 | $6.49 | $7.73 | $9.21 | +0.80% |
| Week 6 | $6.39 | $7.74 | $9.39 | +0.96% |
| Week 7 | $6.30 | $7.76 | $9.55 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
The company develops DM300, a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
It was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. (DMAC) is a healthcare stock currently priced at $8.01. Its market cap is $431.61M and its rank is 3140. The price outlook across the year-by-year forecast shows upside, with 2026 avg $8.01 and 2030 avg $14.61 and 2050 avg $77.72.
The 30-day forecast includes min $5.33, max $10.25 for 2026, and 2030 max $22.09, and 2050 max $154.07. The ROI figures rise over time, with 2030 ROI 82.4, 2040 ROI 346.5, and 2050 ROI 870.3. Sentiment remains BULLISH in the later years.
A major floor 43.6% below — a decisive break under it would weaken the trend.
The nearest floor, 30.5% below — buyers have tended to step in here.
The nearest ceiling, 4.4% above — a clean break opens room to run.
A major ceiling 26.2% above — clearing it would confirm fresh momentum.
Key DMAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.87 | Sell | $7.71 | Sell |
| MA 10 | $7.52 | Buy | $7.45 | Buy |
| MA 20 | $6.70 | Buy | $6.98 | Buy |
| MA 50 | $6.27 | Buy | $6.59 | Buy |
| MA 100 | $6.71 | Buy | $6.69 | Buy |
| MA 200 | $7.19 | Buy | $6.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.94 | Neutral |
| Stoch RSI (14) | 64.03 | Neutral |
| CCI (20) | 77.33 | Neutral |
| Williams %R (14) | -16.04 | Info |
| MACD (12,26,9) | 0.13 | Buy |
| ROC (12) | 22.13 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 83.96 | Sell |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 1.54 | Buy |
| Ultimate (7,14,28) | 74.13 | Sell |
| Momentum (10) | 1.52 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 7.95 | Sell |
| ADX (14) | 30.01 | Buy |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is bullish, with RSI14 at 80. The SMA50 is $6.15 and the SMA200 is $7.17. Support is at $5.33 and resistance at $8.01, framing a near-term range that aligns with the 30-day window.
The 30-day range spans from $6.46 to $9.93, and annualized volatility is 60.0%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.33 | $7.67 | $9.77 | 0% | Neutral | |
| $7.13 | $9.03 | $12.14 | +18% | Neutral | |
| $7.19 | $9.39 | $13.12 | +22% | Bullish | |
| $8.08 | $10.82 | $15.60 | +41% | Bullish | |
| $10.45 | $14.31 | $21.18 | +87% | Bullish | |
| $11.39 | $15.92 | $24.09 | +108% | Bullish | |
| $12.83 | $18.29 | $28.25 | +138% | Bullish | |
| $14.11 | $20.47 | $32.21 | +167% | Bullish | |
| $13.43 | $19.83 | $31.73 | +159% | Bullish | |
| $14.35 | $21.53 | $35.00 | +181% | Bullish | |
| $22.32 | $36.09 | $62.63 | +371% | Bullish | |
| $42.38 | $78.09 | $148.99 | +918% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.33 | $7.67 | $9.08 | +0.00% |
| August 2026 | $6.39 | $7.56 | $9.19 | -1.50% |
| September 2026 | $6.57 | $7.83 | $9.64 | +3.65% |
| October 2026 | $6.64 | $7.96 | $9.90 | +1.67% |
| November 2026 | $6.42 | $7.75 | $9.72 | -2.65% |
| December 2026 | $6.37 | $7.73 | $9.77 | -0.27% |
Click any year to see its month-by-month DMAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DMAC to range from $5.33 to $9.77 through 2026. The $7.67 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DMAC price prediction for 2027 points to an average of $9.03 (low $7.13, high $12.14) — a potential gain of +18% on today's $7.67. A consolidation phase looks the most probable path here.
In 2028, DMAC is projected to trade between $7.19 and $13.12, averaging $9.39 — a potential gain of +22% from today's $7.67. That is up +4% on the projected 2027 average. Momentum favours further upside here.
DiaMedica Therapeutics Inc.'s 2029 outlook centres on $10.82, within a $8.08 to $15.60 range. That is up +15% on the projected 2028 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DMAC could reach as high as $21.18, with a base case around $14.31 and support toward $10.45 — roughly +87% from $7.67. Momentum favours further upside here.
Expect DMAC to range from $11.39 to $24.09 through 2031. The $15.92 average target implies a +108% move from current prices. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DMAC price prediction for 2032 points to an average of $18.29 (low $12.83, high $28.25) — a potential gain of +138% on today's $7.67. Momentum favours further upside here.
In 2033, DMAC is projected to trade between $14.11 and $32.21, averaging $20.47 — a potential gain of +167% from today's $7.67. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
DiaMedica Therapeutics Inc.'s 2034 outlook centres on $19.83, within a $13.43 to $31.73 range. That is -3% versus the projected 2033 average. That marks a +159% change versus current levels. Momentum favours further upside here.
By 2035, DMAC could reach as high as $35.00, with a base case around $21.53 and support toward $14.35 — roughly +181% from $7.67. Buyers look set to stay in control over this stretch.
Expect DMAC to range from $22.32 to $62.63 through 2040. The $36.09 average target implies a +371% move from current prices. That is up +68% on the projected 2035 average. Momentum favours further upside here.
The DMAC price prediction for 2050 points to an average of $78.09 (low $42.38, high $148.99) — a potential gain of +918% on today's $7.67. Buyers look set to stay in control over this stretch.
Investing $1,000 in DMAC today (≈ 130.378096 DMAC) could be worth
$10,180.63
+$9,180.63 (+918%) by 2050 · US Dollar
Based on the average projected DMAC price of $78.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMACwould be worth at today's price.
$1,000 invested in DMAC on Jul 10, 2025 (≈ 272.479558 DMAC) would be worth
$2,089.92
+$1,089.92 (+109.0%) today · 2.09× · US Dollar
Based on a DMAC entry price of $3.67 vs. today's $7.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.62 | $1,006.56 | +0.7% |
| 1 month ago | $5.33 | $1,439.02 | +43.9% |
| 3 months ago | $5.99 | $1,280.47 | +28.0% |
| 6 months ago | $8.14 | $942.26 | -5.8% |
| 1 year ago | $3.67 | $2,089.92 | +109.0% |
| All time (5.0y) ago | $3.97 | $1,931.99 | +93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMAC forecast.
Our base-case forecast reaches $15.00 around 2031.
Implied market cap at $15.00: $808.25M
The multi-year forecast shows a clear path of upside for DiaMedica Therapeutics Inc., with rising average prices across the horizon. In 2030 the avg is $14.61 and the max is $22.09, with a min of $10.46 and ROI 82.4; sentiment is BULLISH.
In 2040 the avg is $35.77 and the max is $64.12, with a min of $21.22 and ROI 346.5; sentiment is BULLISH.
In 2050 the avg is $77.72 and the max is $154.07, with a min of $39.65 and ROI 870.3; sentiment is BULLISH. These are estimates and not guarantees, and actual results depend on a range of factors affecting healthcare equities and execution of clinical programs.
Tap a question to reveal the answer.
2030 avg price $14.61, min $10.46, max $22.09; ROI 82.4; sentiment BULLISH.
Forecasts show bullish sentiment in 2030-2050, with 2030 avg price $14.61 and 2050 avg price $77.72, ROI 82.4 and 870.3 respectively; sentiment BULLISH.
Yes. The forecast shows a 2030 max of $22.09, and later years also reach higher prices (2031 max $24.99; 2032 max $29.64; 2033 max $33.60).
$8.01 and $431.61M.
RSI14 is 80, sentiment is BULLISH, SMA50 is $6.15, SMA200 is $7.17; support $5.33, resistance $8.01; 30-day range $6.46-$9.93; annualized volatility 60.
DiaMedica Therapeutics Inc. Community Discussion
0Share your DiaMedica Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.